Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Objectives: The medications preferred by patients for allergic rhinitis and their usage remain unclear. This study investigated treatment-seeking behaviors in patients with allergic rhinitis, including medical treatments, environmental controls, and surgical treatments.
Methods: In this study, a cross-sectional survey was conducted by internal medicine, pediatric, or otorhinolaryngology physicians at university hospitals from January 2022 to April 2022. A questionnaire was administered to patients with confirmed allergic rhinitis to collect information regarding medical treatments (prescription and over-the-counter medication use patterns, comorbid asthma, and allergen-specific immunotherapy), environmental controls (usage of air purifiers and pet avoidance), and experiences with surgical treatments.
Results: We included 51 patients with allergic rhinitis with a mean age of 31.6±16.0 years. Among them, 47 (92.2%) and 6 (11.8%) patients had pollen allergies and asthma, respectively. Furthermore, 41 (80.4%) patients took prescribed medicines, while 39 (76.5%) patients only used the medication when experiencing symptoms. Thirty patients (58.8%) reported concurrent use of intranasal sprays and oral medications. Thirty-three patients (64.7%) reported awareness of immunotherapy, and there were no preferential differences between subcutaneous (52%) and sublingual immunotherapy (48%). Of the 36 patients (70.6%) who reported using an air purifier, 38.9% considered it helpful in preventing allergic rhinitis symptoms. Fourteen patients (27.5%) currently or previously had a companion animal, with half experiencing worsening of symptoms. Twelve patients had received surgical treatment and reported high satisfaction levels (41.6%, very satisfied; 41.6%, satisfied).
Conclusion: Patients with allergic rhinitis showed similar preferences for oral and spray medications. They also showed satisfaction with surgical treatments and an interest in the environmental management of allergic rhinitis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11685916 | PMC |
| http://dx.doi.org/10.18787/jr.2024.00023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oral immunotherapy in children with allergic diseases: past, present and future.
Minerva Pediatr (Torino)
September 2025
Pediatric Respiratory Unit, Department of Clinical and Experimental Medicine, San Marco Hospital, University of Catania, Catania, Italy.
Allergen immunotherapy (AIT) is the only treatment capable of modifying the natural history of allergic diseases by promoting immune tolerance. Initially developed for respiratory allergies, AIT has expanded to include food allergies, particularly through oral immunotherapy (OIT). This review explores the historical evolution, current applications, and future directions of AIT in pediatric patients.
View Article and Find Full Text PDFCharacteristics and Risk Factors of Pollen-Food Allergy Syndrome in Patients With Hay Fever: A Digital Cross-Sectional Cohort Study Using AllerSearch.
J Investig Allergol Clin Immunol
September 2025
Department of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Background And Objectives: Pollen-food allergy syndrome (PFAS) is a frequent comorbidity in individuals with hay fever. Identifying risk factors and allergen clusters can aid targeted interventions and management strategies. Objective: This study characterizes PFAS in patients with hay fever and identifies associated risk factors using the mobile health platform, AllerSearch.
View Article and Find Full Text PDFAcoustic therapy for allergic rhinitis and chronic rhinosinusitis: modulating microbiome, immunity and well-being.
Front Allergy
August 2025
Department of Surgery, University of Auckland, Auckland, New Zealand.
Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) are common respiratory conditions that significantly impact patient health and contribute to substantial healthcare burdens. While conventional treatments offer symptom relief, many patients continue to experience persistent symptoms, side effects, or resistance to standard therapies. This highlights the growing need for novel, non-invasive, and sustainable therapeutic strategies to manage chronic airway inflammation.
View Article and Find Full Text PDFClinical and Healthcare Cost Characteristics of Severe Asthma Patients with Long-Term Control on Omalizumab: A Comparative Analysis with Patients Who Switched to Other Biologics.
J Asthma Allergy
September 2025
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University Kyoto, Kyoto, Japan.
Background And Purpose: Biologics are crucial for severe asthma treatment, but their high costs pose challenges. Omalizumab (OML) is dosed on the basis of patient-specific factors. The purpose of this study is to clarify the clinical characteristics of severe asthmatics who maintain long-term control on omalizumab including healthcare cost considerations.
View Article and Find Full Text PDFBibliometric analysis of the association between air pollution and allergic rhinitis.
Glob Health Action
December 2025
Department of Otolaryngology, Head & Neck Surgery, Shanxi Medical University Second Affiliated Hospital, Taiyuan, Shanxi Province, China.
Background: Allergic rhinitis (AR) is an increasingly prominent global public health issue, where air pollution significantly contributes to its rising incidence. Although numerous studies have explored the link between air pollution and AR pathogenesis, comprehensive summaries are still limited.
Objective: This study performs a bibliometric analysis to identify research hotspots and emerging trends, offering insights into AR prevention and management.